Please login to the form below

oncolytic viruses

This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... There’s a lot of activity going on in R&D however,

Latest news

J&J pays $140m upfront for cancer-busting virus firm BeneVir

that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer immunotherapies. ... The biotech’s website indicates that its oncolytic viruses lend themselves to co-administration with immune checkpoint
Sanofi’s latecomer PD-1 gets date for FDA verdict

and oncolytic viruses.
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via 210m ViraTherapeutics deal. Option to acquire the Austrian biotech after phase I trials remains open to Boehringer . ... The deal - valued at up to 210m ($236m) - gives Boehringer joint development rights to
BMS to explore new options for its immuno-oncology drug Opdivo

Jean Viallet, global clinical research lead for oncology at BMS, said: “ This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism
Amgen gets FDA nod for virus-based melanoma therapy

The FDA has approved Amgen's Imlygic for melanoma, the first oncolytic virus therapy to get a green light in the US. ... Amgen is also looking at combining the oncolytic virus therapy with Merck &Co's checkpoint inhibitor Keytruda (pembrolizumab) in head

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Gene therapy

From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still
Deal Watch December 2016

995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “ armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.
The Maverick: giving medicines away free

His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Turnstone Biologics bolsters leadership team

Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Products as portfolios: positioning immuno-oncology products

In addition, developments in oncolytic viruses mean the options for patients with certain solid tumours are ever-expanding.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Account Manager: Competitive salary commensurate with experience

Home based, Principal Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Editorial Director – Medical Education (MedComms): Neg

Business Unit Head, Medical Communications, London: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director – Healthcare Advertising - London: Neg

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Subscribe to our email news alerts

PMHub

Add my company

McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....